Pinney Sean P
Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York.
J Card Fail. 2015 Oct;21(10):824-34. doi: 10.1016/j.cardfail.2015.08.005. Epub 2015 Aug 28.
Clinical outcomes for patients with advanced heart failure receiving left ventricular assist devices are driven by appropriate patient selection, refined surgical technique, and coordinated medical care. Perhaps even more important is innovative pump design. The introduction and widespread adoption of continuous-flow ventricular assist devices has led to a paradigm shift within the field of mechanical circulatory support, making the promise of lifetime device therapy closer to reality. The disruption caused by this new technology, on the one hand, produced meaningful improvements in patient survival and quality of life, but also introduced new clinical challenges, such as bleeding, pump thrombosis, and acquired valvular heart disease. Further evolution within this field will require financial investment to sustain innovation leading to a fully implantable, durable, and cost-effective pump for a larger segment of patients with advanced heart failure.
接受左心室辅助装置的晚期心力衰竭患者的临床结局取决于合适的患者选择、精湛的手术技术以及协调的医疗护理。或许更重要的是创新的泵设计。连续流心室辅助装置的引入和广泛应用导致了机械循环支持领域的范式转变，使终身装置治疗的前景更接近现实。一方面，这项新技术带来的变革在患者生存和生活质量方面产生了有意义的改善，但也带来了新的临床挑战，如出血、泵血栓形成和获得性瓣膜性心脏病。该领域的进一步发展将需要资金投入以维持创新，从而为更多晚期心力衰竭患者开发出完全可植入、耐用且经济高效的泵。
